The race to slow human ageing has attracted significant global capital. Quietly and methodically, Vancouver is building the infrastructure to compete for it.
A cluster of UBC-affiliated life sciences firms and hospital-linked research institutes are pivoting toward longevity therapeutics—targeting cellular senescence, metabolic disease, and the molecular biology of ageing. While the $600 billion market projection often conflates longevity interventions with the treatment of specific age-related conditions like Alzheimer’s, the global market for these interventions is projected to exceed $600 billion by 2030.
Vancouver’s play is structural. Three interlocking advantages set it apart: the research depth of UBC’s Faculty of Medicine and its commercialization pipeline; the clinical translation capacity of institutions like the BC Children's Hospital Research Institute and Vancouver Coastal Health Research Institute (VCHRI); and geographic proximity to the Pacific Northwest life sciences corridor.
A concrete infrastructure catalyst is arriving: the expansion of wet-lab space at the Great Northern Way Campus, which adds purpose-built laboratory capacity for commercial-stage tenants. For longevity-focused companies that have outgrown academic incubator space, this fills a critical gap in the ecosystem.
From Discovery to Development
The distinction here is the drug development pipeline. Longevity therapeutics involves molecules, biomarkers, and the capital-intensive path from pre-clinical research to clinical trials.
That path is evolving in Vancouver. UBC’s commercialization office has accelerated spinout activity, with companies focusing on mechanisms such as epigenetics and mitochondrial biology. The university’s research foundation in these areas provides a competitive edge that takes other clusters years to build.
Genome BC remains a consistent early-stage funder, supporting research that bridges academic discovery and commercial application, particularly in precision health and genomics platforms.
The Capital Equation
Proximity to Seattle is increasingly vital as the Pacific Northwest emerges as a life sciences capital cluster. The BC Life Sciences Strategy, now in its third year, is designed to signal to external capital that the province is a stable partner.
For longevity-focused founders, the capital environment has shifted. Dedicated longevity funds have created a new category of institutional investor. Vancouver companies with credible science are now better positioned to pitch this capital.
The challenge remains the Series A gap. While pre-clinical work can be funded through grants and angel capital, the transition to clinical-stage development requires institutional venture commitment that remains underrepresented in Canada compared to the U.S. The Great Northern Way expansion helps by reducing facility overhead, but it does not close the financing gap entirely.
The Bigger Picture
What distinguishes Vancouver’s longevity sector is the specificity of its scientific assets. The BC Tech Association’s life sciences working group has identified that while Vancouver possesses deep research capabilities, it must accelerate commercial infrastructure to capture value locally.
The wet-lab expansion at Great Northern Way is a tangible sign of this progress. Combined with the hospital research network and UBC’s commercialization momentum, it offers founders a credible local base. The $600 billion prize is significant, and the infrastructure is arriving. The question for the province is whether the capital and talent pipeline can scale quickly enough to retain its most promising ventures.
